Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up

European Journal of Gynaecological Oncology

Volumn 30, Issue 6, 2009, Pages 609-615

  Van Dalen, A ^a   Favier, J ^b   Hallensleben, E ^b   Burges, A ^c   Stieber, P ^d   De Bruijn, H W A ^e   Fink, D ^f   Ferrero, A ^g   McGing, P ^h   Harlozinska, A ⁱ   Kainz, Ch ^j   Markowska, J ^k   Molina, R ^l   Sturgeon, C ^m   Bowman, A ⁿ   Einarsson, R ^o   Goike, H ^p  

^a Institute of Tumor Marker Oncology   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF TURIN   (Italy)

^h MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

ⁱ WROCLAW MEDICAL UNIVERSITY   (Poland)

^j Vienna International Center   (Austria)

^k POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^l HOSPITAL CLÍNIC   (Spain)

^m ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁿ WESTERN GENERAL HOSPITAL   (United Kingdom)

^o Fujirebio Diagnostics Inc   (Sweden)

^p IDL Biotech   (Sweden)

more..

Author keywords

CA 125; Ovarian cancer; Prognosis; Survival; TPS

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; LAPAROTOMY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PROGNOSIS;

AGED; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDES; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 70949094434     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mogensen O.: "Prognostic value of CA125 in advanced ovarian cancer". Gynecol. Oncol., 1992, 44, 207.
2. Thigpen J., Vance R., Khansur T.: "Second-line chemotherapy for recurrent carcinoma of the ovary". Cancer, 1993, 71, 1559. (Pubitemid 23056074)
3. Tortolero-Luna G., Mitchell MF., Rhodes-Morris HE.: "Epidemiology and screening of ovarian cancer". Obstet. Gynecol. Clin. North Am., 1994, 21, 1.
4. Guppy A.E., Rustin G.J.S.: "CA125 response: can it replace the traditional response criteria in ovarian cancer?". Oncologist, 2002, 7, 437.
5. Bast R.C. Jr, Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., Baggerly K.A. et al.: "New tumor markers: CA125 and beyond". Int. J. Gynecol. Cancer, 2005, 15 (suppl. 3), 274.
6. Duffy J., Bonfrer J.M., Kulpa J., Rustin G.J.S., Soletormos G., Torre G.C. et al.: "CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use". Int. J. Gynecol. Cancer, 2005, 15, 679. (Pubitemid 41783071)
7. Kenemans P., Yedema C.A., Bon G.G., von Mensdorff-Pouilly S.: "CA125 in gynaecological pathology - a review". Eur. J. Obstet. Gynecol. Reprod. Biol., 1993, 49, 115.
8. Ron I.G., Inbar M., Gelernter I., Lewysihn O., Ayalon D., Dale J. et al.: "Use of CA125 response to predict survival parameters of patients with advanced ovarian cancer". Acta Obstet. Gynecol. Scand., 1994, 73, 658. (Pubitemid 24299125)
9. Yedema C.A., Keneman P., Voorhorst F., Bon G., Schijf C., Beex L. et al.: "CA125 half-life in ovarian cancer: a multivariate survival analysis". Br. J. Cancer, 1993, 67, 1361. (Pubitemid 23172879)
10. Högberg T., Kågedal B.: "Seum half-life of the tumor marker CA125 during induction chemotherapy as a prognostic indicator for survival in ovarian cancer". Acta Obstet. Gynecol. Scand., 1990, 69, 423.
11. Hawkins R.E., Roberts K., Wiltshaw E., Mundy J., Fryatt I.J., McCready V.R.: "The prognostic significance of the half-life of serum CA125 in patients responding to chemotherapy for epithelial ovarian carcinoma". Br. J. Obstet. Gynaecol., 1989, 96, 1395. (Pubitemid 20020045)
12. Van der Burg M.E., Lammes F.B., Verweij J.: "CA125 in ovarian cancer". Neth. J. Med., 1992, 40, 36.
13. Riedinger J.M., Wafflart J., Ricolleau G., Eche N., Larbre H., Basuyau J.P. et al.: "CA125 half-life and CA125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study". Ann. Oncol., 2006, 17, 1234. (Pubitemid 44288214)
14. Jemal A., Thomas A., Murray T., Thun M.: "Cancer statistics 2002". C.A. Cancer J. Clin., 2002, 52, 23.
15. Markmann S., Gerber B., Briese V.: "Prognostic value of CA125 levels during primary therapy". Anticancer Res., 2007, 27, 1837. (Pubitemid 46954684)
16. Markman M., Federico M., Liu P.Y., Hannigan E., Alberts D.: "Significance of early changes in the serum CA125 antigen level on overall survival in advanced ovarian cancer". Gynecol. Oncol., 2006, 103, 195. (Pubitemid 44389869)
17. Prat A., Parera M., Peralta S., Perez-Benavente MA., Garcia A., Gil-Moreno A. et al.: "Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer". Ann. Oncol., 2008, 19, 327. (Pubitemid 351201715)
18. Riedinger J.M., Bonnetain F., Basuyau J.P., Eche N., Larbre H., Dalifard I. et al.: "Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome". Ann. Oncol., 2007, 18, 881. (Pubitemid 47054085)
19. Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., Alberts D.S.: "Pretreatment CA-125 and risk of relapse in advanced ovarian cancer". J. Clin. Oncol., 2006, 24, 1484. (Pubitemid 46622013)
20. Juretzka M.M., Barakat R.R., Chi D.S., Iasonos A., Dupont J., Abu-Rustum N.R. et al.: "CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consoloidation therapy". Gynecol. Oncol., 2007, 104, 176. (Pubitemid 46054121)
21. Schneider D., Halperin R., Halperin D., Bukovsky I., Hadas E.: "Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system". Eur. J. Gynaecol. Oncol., 1998, 19, 547. (Pubitemid 29008295)
22. Mazurek A., Niklinski J., Laudanski T., Pluygers E.: "Clinical tumor markers in ovarian cancer". Eur. J. Cancer Prev., 1998, 7, 23. (Pubitemid 28164133)
23. Stenman UH., Alfthan H., Vartiainen J., Lehtovirta P.: "Markers supplementing CA125 in ovarian cancer". Ann. Med., 1995, 27, 115.
24. Rydlander L., Ziegler E., Bergman T., Schöberl E., Steiner G., Bergman A.C. et al.: "Molecular characterization of a tissue-polypeptide- specific-antigen epitope and its relationship to human cytokeratin 18". Eur. J. Biochem., 1996, 241, 309. (Pubitemid 26356814)
25. Van Dalen A., Heering KJ., Barak V., Peretz T., Cremaschi A., Geroni P. et al.: "Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumor marker changes". Breast, 1996, 5, 82. (Pubitemid 26130313)
26. Blokkebak-Poulsen J., Mogensen O., Mogensen B.: "Tissue polypeptide-specific antigen (TPS) as tumor marker in epithelial ovarian cancer". Acta Oncol., 1997, 36, 433. (Pubitemid 27298565)
27. Sarandakou A, Phocas I, Sikiotis K, Rizos D, Kalambokis D, Trakakis E. et al.: "Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer". Eur. J. Gynaecol. Oncol., 1998, 19, 73. (Pubitemid 28040701)
28. Tempfer C., Hefler L., Haeusler G., Reinthaller A., Koelbl H, Zeisler H. et al.: "Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients". Int. J. Cancer (Pred. Oncol.), 1998, 79, 241. (Pubitemid 28262207)
29. Van Dalen A., Favier J., Burges A., Hasholzner U., de Bruijn H.W.A., Dobler-Girdziunaite D. et al.: "Prognostic significance of CA125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients". Gynecol. Oncol., 2000, 79, 444.
30. Yeh L.S., Hung Y.C., Kao A., Lin CC., Lee C.C.: "Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA125) in the early prediction of recurrent ovarian cancer". Anticancer Res., 2002, 122, 3669. (Pubitemid 36132847)
31. Van Dalen A., Favier J., Burges A., Hasholzner U., de Bruijn HWA., Dobler-Girdziunaite D. et al.: "Serum levels of CA125 and TPS during treatment of ovarian cancer". Anticancer Res., 2000, 20, 5107. (Pubitemid 32319089)
32. Barak V., Goike H., Panaretakis KW., Einarsson R.: "Clinical utility of cytokeratins as tumor markers". Clin. Biochem., 2004, 37, 529. (Pubitemid 38845016)
33. Sturgeon C., Duffy M.J., Stenman U.H., Lilja H., Brünner N., Chan D.W. et al.: "National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancer". Clin. Chem., 2008, 54, 11. (Pubitemid 352777353)